Compare OFIX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | RCEL |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.0M | 360.9M |
| IPO Year | 1998 | 2018 |
| Metric | OFIX | RCEL |
|---|---|---|
| Price | $8.89 | $13.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $13.00 | $12.07 |
| AVG Volume (30 Days) | ★ 381.3K | 281.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 27.20 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | $71,610,000.00 |
| Revenue This Year | $3.48 | $21.81 |
| Revenue Next Year | $2.46 | $25.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.85 | ★ 11.45 |
| 52 Week Low | $8.50 | $3.22 |
| 52 Week High | $16.99 | $13.50 |
| Indicator | OFIX | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 71.16 |
| Support Level | $8.68 | $3.74 |
| Resistance Level | $9.92 | N/A |
| Average True Range (ATR) | 0.42 | 0.70 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 30.03 | 87.35 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.